Phosphatase News and Research

RSS

Study could lead to non-surgical alternatives for tonsillectomies

Children with obstructive sleep apnea (OSA) may one day be able to have an injection or use a throat spray instead of getting their tonsils removed to cure their snoring, according to a new study from the University of Chicago, which found that a specific gene product may be responsible for the proliferation of adenotonsillar tissue that can cause pediatric OSA.

4 Feb 2010

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Researchers at the Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University in Montreal have discovered a previously unsuspected link between two different genetic pathways which suppress the growth of cancer tumours.

8 Jan 2010

GIVI scientists discover anti-HIV molecule that enhances infection, reduces transmission

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have discovered a new agent that might inhibit the infectivity of HIV. The agent, surfen, impairs the action of a factor in semen that greatly enhances the viral infection.

5 Jan 2010

Phosphatases can prevent inflammation and formation of blood clots

Polyphosphate from blood platelets plays a key role in inflammation and the formation of blood clots, scientists from the Swedish medical university Karolinska Institutet have shown. The study, which is presented in the prestigious scientific journal Cell, describes how this mechanism can be used in treatment.

11 Dec 2009

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009

Enobia Pharma initiates study of bone-targeted enzyme replacement therapy for hypophosphatasia

Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). The six-month study will assess the safety, efficacy and pharmacokinetics of ENB-0040 in up to 12 children with HPP.

4 Nov 2009

Positive results from Phase II clinical trial of INT-747 announced

Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC).

27 Oct 2009

DaVita to demonstrate clinical outcomes, patient care and nutrition through 43 abstracts

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research®, today announced that company representatives will deliver 43 abstracts—40 posters and three oral presentations—at this year’s American Society of Nephrology’s (ASN) Renal Week to be held in San Diego, Calif., from Oct. 27 – Nov. 1, 2009.

24 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

PP5 enzyme decrease in neurons can cause cell death in Alzheimer's disease patients

A Purdue University researcher has discovered that the amount of an enzyme present in neurons can affect the mechanism thought to cause cell death in Alzheimer's disease patients and may have applications for other diseases such as stroke and heart attack.

8 Oct 2009

Genetic factors play an important role in the development of type 1 diabetes

Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.

30 Sep 2009

Researchers study the role of stem cells in development of liver cancer

Penn State College of Medicine researchers, in collaboration with colleagues at the University of Southern California, have taken an important step in understanding the role of stem cells in development of liver cancer.

18 Sep 2009

Enobia Pharma's clinical study of ENB-0040 for treating hypophosphatasia provides positive results

Enobia Pharma today announced positive data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After six months of treatment with ENB-0040, four of five severely affected patients showed marked improvements in bone mineralization, correction of skeletal defects, better respiratory function, including weaning from assisted ventilation, and cognitive and motor development.

14 Sep 2009

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial demonstrating that ACE-031 increased lean body mass and muscle volume. The results from this randomized, placebo-controlled study were presented at the 14th International Congress of the World Muscle Society in Geneva, Switzerland.

10 Sep 2009

Ipsen grants license to Debiopharm for developing and commercialising cancer treatment

Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.

7 Sep 2009

Debiopharm granted license to develop and commercialise CDC25

Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen’s first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.